SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dishman Carbogen Amcis informs about press release

28 Oct 2021 Evaluate
Dishman Carbogen Amcis has informed that the Company's wholly owned subsidiary namely CARBOGEN AMCIS SAS, France, announces the release of a new batch for clinical trials of AGuIX Drug Product for NH TherAguix, a clinical stage company developing innovative nano medicine for the treatment of cancer. In this regard, it enclosed Press Release.

The above information is a part of company’s filings submitted to BSE.

Dishman Carbogen Amc Share Price

168.60 -2.00 (-1.17%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×